News
- Author:
- Will Pass
Publish date: December 11, 2018
Data “suggest that IgAV should not be considered a ‘single-hit’ disease.”
News
- Author:
- Will Pass
Publish date: December 6, 2018
Genomic analysis showed telomere maintenance mechanisms, RAS mutations, and p53 mutations were strongly associated with outcome and other disease c...
News
- Author:
- Will Pass
Publish date: December 5, 2018
Future efforts should aim to link genetic knowledge with prognosis and treatment selection.
News
- Author:
- Will Pass
Publish date: December 4, 2018
Disease-specific survival was lowest in ccRCC patients with high human telomerase reverse transcriptase protein expression.
News
- Author:
- Will Pass
Publish date: December 4, 2018
Older patients with ccRCC may respond better than younger patients to phosphoinositide 3-kinase (PI3K) or checkpoint inhibition because of age-rela...
News
- Author:
- Will Pass
Publish date: November 20, 2018
A retrospective study suggests elderly patients with non-Hodgkin lymphoma (NHL) are more likely to die, but not relapse, within a year of allogenei...
News
- Author:
- Will Pass
Publish date: November 10, 2018
The large outcomes trial didn’t show a benefit in major adverse cardiovascular events.
News
- Author:
- Will Pass
Publish date: November 9, 2018
Patients undergoing complete surgical resection for brain mets were at much higher risk of local recurrence than patients.
News
- Author:
- Will Pass
Publish date: October 25, 2018
Concerns about an elevated cardiovascular disease risk in hemophilia A patients may be unfounded, a new study suggests.
News
- Author:
- Will Pass
Publish date: October 25, 2018
The 3-year overall survival rate for patients treated with nivolumab was 51.2%, compared with 21.6% for those who received dacarbazine.
News
- Author:
- Will Pass
Publish date: October 24, 2018
The researchers said older age was an independent risk factor for nonrelapse mortality.
News
- Author:
- Will Pass
Publish date: October 23, 2018
MUNICH – Data from a large retrospective study of metastatic breast cancer indicates that, in general, men and women received similar treatments an...
News
- Author:
- Will Pass
Publish date: October 23, 2018
MUNICH – No immune-related adverse events or deaths due to drug toxicity occurred in cancer patients with HIV treated with nivolumab.
News
- Author:
- Will Pass
Publish date: October 22, 2018
MUNICH - Olaparib maintenance therapy reduced risk of disease progression or death by 70% compared with placebo in SOLO-1.
News
- Author:
- Will Pass
Publish date: October 22, 2018
MUNICH – Erlotinib for stage IIIA (N2) NSCLC may increase progression-free survival, but clinical benefits fall short...
